Immuneering Corporation

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

Immuneering reported Q3 2026 results with a net loss of $24.2 million ($0.37 per share) and $166.1 million in cash, guiding runway into Q4 2028. The key clinical news is positive: Phase 2 pancreatic cancer follow-up was extended because patients on atebimetinib + mGnP are living longer than projected, with updated N=55 data due in 1H 2027. Phase 3 MAPKeeper 301 enrollment is ahead of schedule, prompting an expansion of the target from 510 to approximately 570 patients and the potential to accelerate the mid-2028 topline readout. R&D spend roughly doubled year-over-year to $20.7 million on Phase 3 activity and commercial readiness, driving the larger cash burn against the prior $217.0 million year-end cash position.

•3d ago

Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026

Immuneering presented the design and methodology of its ongoing pivotal Phase 3 MAPKeeper 301 trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer in a trial-in-progress poster at ESMO 2026. The global, randomized trial tests overall survival as its primary endpoint versus standard-of-care gemcitabine/nab-paclitaxel, with dosing underway since June 2026. The Phase 3 builds on Phase 2a results reported at ASCO showing 17.3-month median overall survival, 8.3-month PFS, 36% ORR and 82% disease control among 55 patients, though not head-to-head against the control arm.

•6d ago

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering will present a poster at the 41st Annual SITC meeting (November 4-8, 2026, Phoenix) showing that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant preclinical tumor models. The findings provide mechanistic support for a planned Phase 2 study of atebimetinib combined with PD-1 blockade in lung cancer patients. Atebimetinib is Immuneering's lead oral, once-daily MEK inhibitor; the company is also running the pivotal MAPKeeper 301 trial in first-line pancreatic cancer.

•0mo ago

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

Immuneering presented new data at the 2026 AACR Conference on Pancreatic Cancer supporting atebimetinib + mGnP's dual mechanism of tumor volume reduction and body mass preservation in first-line pancreatic cancer. In exploratory post-hoc analyses from the Phase 2a study, stable or increased weight was roughly twice as common among treated patients (n=23) versus a published benchmark, and weight-stable patients had significantly longer overall survival (HR=3.13; p=0.049). The findings build on the previously reported 17.3-month median overall survival in 55 first-line pancreatic cancer patients at ASCO 2026; the Phase 3 MAPKeeper 301 trial (NCT07562152) is actively enrolling.

•1mo ago

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

Immuneering (Nasdaq: IMRX) will present a poster at the AACR Conference on Pancreatic Cancer in San Diego, September 25-28, 2026, titled Atebimetinib Reduces Tumor Volume and Preserves Body Mass: A Dual Mechanism for Extended Survival in Pancreatic Cancer. The poster expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib plus mGnP maintained or gained weight at three months. Atebimetinib, an oral once-daily MEK inhibitor, is being tested in the global randomized pivotal MAPKeeper 301 trial in first-line pancreatic cancer; Dr. Peter Vu of UC San Diego Health presents the poster during the September 26 session.

•1mo ago

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Immuneering commented on a competitor's FDA approval for second-line pancreatic cancer, using the news to highlight its own focus on first-line treatment with atebimetinib. The company reiterated Phase 2a data showing 17.3 months median overall survival for atebimetinib combined with chemotherapy, with 84% of patients maintaining or gaining weight at three months. A global Phase 3 pivotal trial, MAPKeeper 301, is currently enrolling patients to evaluate the treatment in the first-line metastatic setting.

•2mo ago

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Immuneering reported Q2 net loss of $17.3 million ($0.27 per share) with cash, equivalents and marketable securities of $182.7 million, which management expects to fund operations into 2029. The company initiated dosing in its pivotal Phase 3 MAPKeeper 301 trial evaluating atebimetinib in first-line pancreatic cancer, following Phase 2a data showing a median overall survival of 17.3 months in 55 patients. Additionally, Immuneering appointed Andrew Gengos as Chief Financial Officer and published peer-reviewed data in Cancer Research supporting atebimetinib’s mechanism of action.

•2mo ago

Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

Immuneering announced the publication of a study in Cancer Research validating the preclinical activity and tolerability of its lead candidate atebimetinib. The study showed that atebimetinib achieved deeper and more durable tumor growth inhibition than the approved MEK inhibitor binimetinib and prevented cancer cachexia in animal models. The company is currently recruiting for the Phase 3 MAPKeeper 301 trial in pancreatic cancer and expects to dose the first patient in a Phase 2 lung cancer trial in the second half of the year.

•3mo ago

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering appointed Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Gengos joins from Terns Pharmaceuticals, which was acquired by Merck for $6.7 billion, bringing over 25 years of biotech leadership experience. He will oversee financial strategy, capital allocation, and business development as the company advances its lead candidate atebimetinib through Phase 3 trials in pancreatic cancer.

•4mo ago

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering has dosed the first patient in MAPKeeper 301, a pivotal Phase 3 trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer. The global, randomized study compares the combination therapy against standard GnP alone, with overall survival as the primary endpoint. Topline data, including the primary endpoint readout, is anticipated in mid-2028, providing a clear timeline for the next major catalyst.

•4mo ago

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering presented oral data at ASCO showing atebimetinib plus chemotherapy achieved a median overall survival of 17.3 months in 55 first-line pancreatic cancer patients, compared to 8.5 months for standard of care. The regimen demonstrated a favorable safety profile with only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy-related, and no Grade 4 or 5 atebimetinib-related events. 84% of participants maintained or gained weight at three months, supporting preserved functional status. The company is actively recruiting for the pivotal Phase 3 MAPKeeper 301 trial, with first patient dosing expected in mid-2026.

•5mo ago

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering reported a 17.3-month median overall survival in its Phase 2a trial of atebimetinib plus chemotherapy for first-line metastatic pancreatic cancer. The safety profile was favorable, with only anemia and neutropenia observed as Grade 3+ treatment-related adverse events in ≥10% of patients, both attributed to chemotherapy. Full data from 55 patients will be presented orally at the ASCO Annual Meeting on June 1, 2026, supporting the recruitment of the pivotal Phase 3 MAPKeeper 301 trial.

•5mo ago

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Immuneering reported Q1 2026 financial results with a net loss of $13.5 million ($0.21 per share), an improvement from the $15.0 million loss in Q1 2025. The company ended the quarter with $198.6 million in cash and marketable securities, maintaining a runway into 2029. Clinically, Immuneering highlighted an upcoming oral presentation at the ASCO Annual Meeting on June 1, featuring new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib plus mGnP in its Phase 2a trial. The pivotal Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer is now recruiting, with first patient dosing on track for mid-2026. The company also noted a case study of a third-line pancreatic cancer patient on atebimetinib monotherapy who has achieved 27 months of progression-free survival with an 85% reduction in tumor burden. A Phase 2 lung cancer trial combining atebimetinib with Libtayo is expected to dose its first patient in the second half of 2026.

•5mo ago

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

Immuneering announced that updated survival data from a Phase 2a trial of atebimetinib plus mGnP in first-line pancreatic cancer will be presented in an oral session at the 2026 ASCO Annual Meeting. The presentation will feature an expanded cohort of 55 patients, which includes the initial 34 patients previously reported plus an additional 21. CEO Ben Zeskind noted that the drug's three mechanisms are designed to promote survival by shrinking tumors durably, preserving body mass, and maximizing tolerability.

•6mo ago